Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Long-Term Study of EN3835 in Edematous Fibrosclerotic Panniculopathy (Cellulite)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03526549
Recruitment Status : Active, not recruiting
First Posted : May 16, 2018
Last Update Posted : July 27, 2020
Sponsor:
Information provided by (Responsible Party):
Endo Pharmaceuticals

Brief Summary:
A Phase 3b, Open-Label Extension Study to evaluate safety and how long response of EN3835 lasts in the treatment of Cellulite.

Condition or disease Intervention/treatment Phase
Edematous Fibrosclerotic Panniculopathy Cellulite Biological: EN3835 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 420 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3b, Open-Label, Long-Term Study to Evaluate the Safety and Temporal Pattern of Response of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Actual Study Start Date : April 26, 2018
Estimated Primary Completion Date : October 2023
Estimated Study Completion Date : October 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Edema

Arm Intervention/treatment
Experimental: EN3835 Active
EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)
Biological: EN3835
Collagenase Clostridium Histolyticum (CCH)
Other Name: Xiaflex




Primary Outcome Measures :
  1. Proportion of subjects who lose their response as compared to Day 71 of EN3835-302/303 [ Time Frame: 60 months ]
    Measured by proportion of subjects that both the Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS) and Patient Reported Photonumeric Cellulite Severity Scale (PR-PCSS) scores/ratings return to baseline of the double-blind studies (EN3835-302/303) or worse; both CR-PCSS and PR-PCSS worsened 2-levels compared to the score at Day 71 of the double-blind studies (EN3835-302/303); either CR-PCSS or PR-PCSS worsened 2-levels compared to the scores at Day 71 of the double-blind studies (EN3835-302/303); both CR-PCSS and PR-PCSS scores worsened by 1-level compared to the corresponding scores at Day 71 of the double-blind studies (EN3835-302/303)


Secondary Outcome Measures :
  1. Proportion of subjects at each level of improvement in the PR-PCSS [ Time Frame: 60 months ]
    Scale is 5 levels, 0=None to 4=Severe

  2. Proportion of subjects at each level of improvement in the CR-PCSS [ Time Frame: 60 months ]
    Scale is 5 levels, 0=None to 4=Severe

  3. Changes in the Patient Reported Cellulite Impact Scale (PR-CIS) from Baseline (Day 1) of EN3835-302/303 [ Time Frame: 60 months ]
    Scale is 11 levels; 0=Not at All to 10=Extremely

  4. Proportion of subjects at each level of improvement in the Subject Satisfaction with cellulite treatment [ Time Frame: 60 months ]
    Scale is 5 levels; -2=Very dissatisfied to +2=Very satisfied

  5. Proportion of subjects at each level of improvement in the subject self-rating scale [ Time Frame: 60 months ]
    Scale is 7 levels; 0=Extremely dissatisfied to 6=Extremely satisfied



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

All Subjects (Through Day 180):

  1. Voluntarily sign and date an informed consent agreement
  2. Have participated in and completed the double-blind Phase 3 study EN3835-302 or EN3835-303
  3. Be willing to apply sunscreen to the buttocks before each exposure to the sun while participating in the study
  4. Be judged to be in good health
  5. Be willing and able to cooperate with the requirements of the study
  6. Be able to read, complete and understand the patient reported outcomes rating instruments in English.

In addition to inclusion Criteria for All Subjects Through Day 180, additional Inclusion Criteria are listed below:

Inclusion Criteria - Category I Subjects:

  1. Received active EN3835 in study EN3835-302 or EN3835-303
  2. Maximum composite response at Day 71 in either or both buttocks in double-blind study EN3835-302 or EN3835-303 was ONLY a 1-level improvement on CR-PCSS/PR-PCSS

Inclusion Criteria - Category II Subjects:

  1. Received active EN3835 in study EN3835-302 or EN3835-303
  2. Maximum composite response at Day 71 in either or both buttocks in double-blind study EN3835-302 or EN3835-303 was at least a 2-level composite improvement on CR-PCSS/PR-PCSS

Inclusion Criteria - Category III Subjects:

1. Received active EN3835 in study EN3835-302 or EN3835-303 but did not meet eligibility criteria for Category I or Category II status

Inclusion Criteria - Retreatment Subjects (Eligible Category I and Category II Subjects Whom opt to Receive Retreatment):

1. Have a negative serum pregnancy test

Exclusion Criteria

All Subjects (Through Day 180):

  1. Intends to or has used any of the local applications/therapies/injections/procedures that restricts study participation
  2. Intends to use tanning spray or tanning booths during this period
  3. Has received or intends to receive an investigational drug or treatment, other than the treatment received in study EN3835-302/303 during this period
  4. Any other condition(s) that, in the Investigator's opinion, might indicate the subject to be unsuitable for the study

In addition to Exclusion Criteria for All Subjects Through Day 180, additional Exclusion Criteria also apply to Category I and Category II subjects:

Exclusion Criteria - Category I and Category II Subjects (Post Day 180):

1. Has received any collagenase treatments at any time since completion of the double-blind study (EN3835-302 or EN3835-303).

Exclusion Criteria for Subjects Whom opt for Observations Only (ie, no retreatment): None

Exclusion Criteria - Category II Subjects:

Exclusion criteria for Subjects Whom opt for Observation Only (ie, no retreatment): None

Exclusion Criteria - Category III Subjects: None

Exclusion Criteria - Retreatment Subjects (Eligible Category I and Category II Subjects Whom opt to Receive Retreatment):

  1. Has systemic conditions (coagulation disorders, malignancy, keloidal scar, adnormal wound healing) that restricts study participation
  2. Has local (in areas to be treated) conditions (thrombosis, vascular disorder, active infection/inflammation, skin laxity, flaccidity and/or skin sagging, active cutaneous alteration, tattoo/mole) that restricts study participation
  3. Requires anticoagulant or antiplatelet medication during the study
  4. Prior to and during the course of retreatment (Treatment Visit 1 through Treatment Visit 4), is nursing or providing breast milk in any manner
  5. Prior to and during the course of retreatment (Treatment Visit 1 through Treatment Visit 4), intends to become pregnant during the study
  6. Prior to and during the course of retreatment (Treatment Visit 1 through Treatment Visit 4), intends to use tanning spray or tanning booths during the study
  7. Has received an investigational drug or treatment, other than treatment in study EN3835-302/303, within 30 days before retreatment with study drug
  8. Has a known systemic allergy to collagenase or any other excipient of study drug
  9. Has received any collagenase treatments at any time since completion of the double-blind study
  10. Any other condition(s) that, in the Investigator's opinion, might indicate the subject to be unsuitable for Category II retreatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03526549


Locations
Show Show 42 study locations
Sponsors and Collaborators
Endo Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Michael McLane, PhD Endo Pharmaceuticals
Layout table for additonal information
Responsible Party: Endo Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03526549    
Other Study ID Numbers: EN3835-304
First Posted: May 16, 2018    Key Record Dates
Last Update Posted: July 27, 2020
Last Verified: July 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cellulite
Edema
Skin Manifestations